These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20166202)

  • 41. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
    Rowinsky EK; Schwartz JD; Zojwalla N; Youssoufian H; Fox F; Pultar P; Novosyadlyy R; Cosaert J; Ludwig DL
    Curr Drug Targets; 2011 Dec; 12(14):2016-33. PubMed ID: 21777192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.
    Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Reynolds CP; Kang MH; Billups CA; Collins J; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Mar; 63(3):443-50. PubMed ID: 26797892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial testing of lenalidomide by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock R; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):606-11. PubMed ID: 21360651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.
    Gorlick R; Maris JM; Houghton PJ; Lock R; Carol H; Kurmasheva RT; Kolb EA; Keir ST; Reynolds CP; Kang MH; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Sep; 59(3):518-24. PubMed ID: 22102563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
    Kurmasheva RT; Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Kang M; Reynolds CP; Wu J; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
    Lock R; Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1181-9. PubMed ID: 18085673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts.
    Wang Y; Lipari P; Wang X; Hailey J; Liang L; Ramos R; Liu M; Pachter JA; Bishop WR; Wang Y
    Mol Cancer Ther; 2010 Feb; 9(2):410-8. PubMed ID: 20124453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
    Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB
    Pediatr Blood Cancer; 2010 Dec; 55(7):1329-37. PubMed ID: 20740623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
    Carol H; Gorlick R; Kolb EA; Morton CL; Manesh DM; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R
    Pediatr Blood Cancer; 2014 Feb; 61(2):245-52. PubMed ID: 24038993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
    Houghton PJ; Gorlick R; Kolb EA; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Feb; 58(2):191-9. PubMed ID: 21337679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).
    Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA
    Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
    Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts.
    Konijeti R; Koyama S; Gray A; Barnard RJ; Said JW; Castor B; Elashoff D; Wan J; Beltran PJ; Calzone FJ; Cohen P; Galet C; Aronson WJ
    Mol Cancer Ther; 2012 Jul; 11(7):1539-46. PubMed ID: 22562985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
    Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
    Morton CL; Houghton PJ; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Aug; 55(2):295-303. PubMed ID: 20582972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.